Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903 [Phase 1]

View source ↗

Summary

Phase 1 study of RP903 conducted by Risen (Suzhou) Pharma Tech Co., Ltd. has completed, evaluating safety, tolerability, pharmacokinetics, efficacy and indicati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Cervical Cancer
• Endometrial Cancer
• Ovarian Cancer
• Solid Tumors

Drugs mentioned

• RP903

Snippet

Sponsor: Risen (Suzhou) Pharma Tech Co., Ltd. | Conditions: Ovarian Cancer, Cervical Cancer | Phase 1 | Status: COMPLETED